Browsing Tag
Karen Chagin
1 post
Why Context Therapeutics (NASDAQ: CNTX) jumped on CTIM-76 fast track status and what comes next
Context Therapeutics stock rose after CTIM-76 won FDA fast track status. Read what it means for CNTX, ovarian cancer strategy, and the June 2026 data catalyst.